Last Updated on October 17, 2024 by The Health Master
Alembic Pharma today announced that its wholly owned subsidiary, Aleor Dermaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Docosanol cream, 10% (OTC).
The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Abreva Cream, 10% (OTC), of GlaxoSmithKline Consumer Healthcare.
Docosanol Cream, 10% (OTC) is used for cold sore/fever blisters on the face or lips, Alembic Pharma said in a statement.
Docosanol Cream, 10% (OTC) has an estimated market size of $60 million for twelve months ending December 2021, according to IQVIA, the statement added.
USFDA gives nod to these companies for Bortezomib for injection
USFDA grants approval for drug to treat spondylitis
USFDA approves this oral heart disease drug
USFDA gives tentative nod to Alembic Pharma for Ivabradine tablets
USFDA gives nod to Lupin for Desvenlafaxine ER tablets
USFDA authorises first C-19 diagnostic test using breath samples
USFDA gives nod to these companies for Bortezomib for injection
Israel opens world’s most protected Blood Bank
USFDA grants approval for drug to treat spondylitis
A smarter way to develop new drugs
DCGI extends timeline for Pharma Firms to regularize 294 FDCs
Medical Degrees from Pakistan declared invalid by NMC
Himachal Pharma firms battle higher input costs
Medical Degrees from Pakistan declared invalid by NMC
USFDA approves this oral heart disease drug
Latest Notifications regarding Pharmaceuticals
